A total of 96 monotherapies with carbamazepine, phenytoin, phenobarbital or primidone, were analyzed in 42 patients with partial epilepsy. Patients who presented a seizure frequency reduction of 75% or more during the second or third monotherapy, were considered to be improved. Out of the 54 comparisons actuated among these monotherapies, only a scanty percentage of cases, evaluated in 16.7%, presented a significant improvement in seizure frequency. Among non-responding patients, the seizure frequency observed with single monotherapies is practically unchanged, when analyzed with Fischer test.
Canger, R., Canevini, M., Cornaggia, C., Giuccioli, D., Pruneri, C. (1985). Carbamazepina, fenitoina, fenobarbital nelle epilessie parziali farmacoresistenti. In R. Canger, M.R. Tata, C.M. Cornaggia, M.P. Canevini, D. Giuccioli (a cura di), Progressi in epilettologia 1985 (pp. 191-193). Lega italiana contro l'epilessia.
Carbamazepina, fenitoina, fenobarbital nelle epilessie parziali farmacoresistenti
CORNAGGIA, CESARE MARIA;
1985
Abstract
A total of 96 monotherapies with carbamazepine, phenytoin, phenobarbital or primidone, were analyzed in 42 patients with partial epilepsy. Patients who presented a seizure frequency reduction of 75% or more during the second or third monotherapy, were considered to be improved. Out of the 54 comparisons actuated among these monotherapies, only a scanty percentage of cases, evaluated in 16.7%, presented a significant improvement in seizure frequency. Among non-responding patients, the seizure frequency observed with single monotherapies is practically unchanged, when analyzed with Fischer test.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
